All Updates

All Updates

icon
Filter
FDA approval
BMS’ Breyanzi receives FDA approval for mantle cell lymphoma
Cell & Gene Therapy
May 30, 2024
This week:
Geographic expansion
Partnerships
Lemonade partners with Homesite to expand home insurance services
InsurTech: Personal Lines
Jun 14, 2024
Funding
BayaniPay raises USD 3 million in seed funding to expand payment solutions
Neobanks
Jun 14, 2024
Partnerships
Carbonfuture and Swiss Re partner for long-term carbon removal through biochar
Carbon Management Software
Jun 13, 2024
Funding
Sidekick raises GBP 8.5 million in seed and debt funding to support expansion
Retail Trading Infrastructure
Jun 13, 2024
Partnerships
Climatiq and Epicor partner to reduce CO2 emissions in supply chains
Carbon Management Software
Jun 13, 2024
Product updates
EHang's pilotless eVTOL aircraft concludes first flight launch in Saudi Arabia
Passenger eVTOL Aircraft
Jun 13, 2024
Partnerships
Skyports partners with Unified Aviation to accelerate global network release
Passenger eVTOL Aircraft
Jun 13, 2024
Industry news
Partnerships
USSF chooses Blue Origin, SpaceX, and ULA for ~USD 5.6 billion Pentagon launch contracts
Space Travel and Exploration Tech
Jun 13, 2024
Funding
AnyCreek raises USD 1.8 million in seed funding to enhance platform and expand into new markets
Travel Tech
Jun 13, 2024
Funding
Zeta Labs raises USD 2.9 million in pre-seed funding to develop autonomous AI agent
Generative AI Applications
Jun 13, 2024
Cell & Gene Therapy

Cell & Gene Therapy

May 30, 2024

BMS’ Breyanzi receives FDA approval for mantle cell lymphoma

FDA approval

  • Bristol Myers Squibb (BMS) has received FDA approval for its one-time CAR T therapy, Breyanzi, to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have undergone a minimum of two lines of systemic therapy, inclusive of Bruton tyrosine kinase inhibitor.

  • This approval is based on Breyanzi’s performance in the TRANSCEND-NHL-001 study of patients with various types of relapsed or refractory B-cell non-Hodgkin lymphoma. Breyanzi demonstrated a highly consistent safety profile and high rates of lasting responses over 18 months.

  • Breyanzi reportedly marks the first CAR T therapy to receive FDA approval to treat four non-Hodgkin lymphoma subtypes, which include relapsed or refractory follicular lymphoma ( May 2024 ), chronic lymphocytic leukemia, and small lymphocytic lymphoma ( March 2024 ).

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.